Q-omics provides the consensus-scored TMEM121B profile across patient tissues and cancer cell-line models. TMEM121B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TMEM121B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TMEM121B RNA expression shows 16,960 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KIRC, and UVM as cancer lineages where TMEM121B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM121B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM121B survival associations across molecular data types. TMEM121B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM121B RNA expression–survival associations across cancer types. High TMEM121B expression shows unfavorable associations in UVM, LIHC and COAD, but favorable associations in STAD, HNSC and LGG. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TMEM121B RNA expression.
This table summarizes TMEM121B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM121B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM121B shows higher tumor expression in KIRC, THCA, KIRP, STAD, CHOL and LIHC. The KIRC box plot shows higher TMEM121B RNA expression in tumor versus normal tissue (log2 FC = +0.681, t-test p < 0.001).
This table shows molecular features associated with TMEM121B in patient tissues and cancer cell lines. In patient samples, TMEM121B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM121B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
